Chemiluminescent Immunoassay
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Anti-Remsima™ antibody,Anti-Renflexis™ antibody,Anti-infliximab antibody,Anti-Remicade® antibody
Specimen requirements | |
|---|---|
| Patient preparation | Dietary supplements containing biotin may interfere in assays and may skew results to be either falsely high or falsely low. For patients receiving the recommended daily doses of biotin, draw samples at least 8 hours following the last biotin supplementation. For patients on mega-doses of biotin supplements, draw samples at least 72 hours following the last biotin supplementation. Collect immediately before next scheduled dose (trough specimen). |
| Preferred specimen(s) | 0.6 mL serum |
| Minimum volume | 0.4 mL |
| Transport container | Transport tube |
| Transport temperature | Refrigerated (cold packs) |
| Specimen stability | Room temperature: 48 hours Refrigerated: 14 days Frozen -20° C: 28 days Frozen -70° C: 70 days |
| Reject criteria | Moderate and gross hemolysis |
Reference ranges are provided as general guidance only. To interpret test results use the reference range in the laboratory report.
*The CPT codes provided are based on AMA guidance and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
This material contains content from LOINC® (http://loinc.org). The LOINC Table, LOINC Table Core are copyright © 1995-2019, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license at http://loinc.org/license.
The tests listed by specialty and category are a select group of tests offered. For a complete list of Quest Diagnostics tests, please adjust the filter options chosen, or refer to our Directory of Services.